Project is to develop anticancer drug candidate with DNA methyltransferase(DNMT) inhibitor, which is one of the well-known targets in epigenetics area. DNMT enzyme catalyzes the transfer of a methyl group to DNA. Hypermethylation of DNA is known for being engaged in carcinogenesis. DNMT inhibitors may reactivate tumor suppressor gene and suppress tumor growth.

Based on the mechanism of DNMT inhibition, we are trying to develop novel orally active drugs with reducing side effects & toxicity and improved pharmacokinetic profile.